loading page

Efficacy and safety of low-dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1
  • +5
  • Yusuke Okayama,
  • Teruhito Takakuwa,
  • Ippei Otomaru,
  • mirei horiuchi,
  • Akiko Miura,
  • Taku Araki,
  • Yotaro Fujitani,
  • Ryosuke Yamamura
Yusuke Okayama
Osaka City University Graduate School of Medicine Department of Hematology
Author Profile
Teruhito Takakuwa
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Ippei Otomaru
Saiseikai Nakatsu Hospital
Author Profile
mirei horiuchi
Saiseikai Nakatsu Hospital
Author Profile
Akiko Miura
Saiseikai Nakatsu Hospital
Author Profile
Taku Araki
Saiseikai Nakatsu Hospital
Author Profile
Yotaro Fujitani
Saiseikai Nakatsu Hospital
Author Profile
Ryosuke Yamamura
Saiseikai Nakatsu Hospital
Author Profile

Abstract

Optimal treatment for Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph+ MPAL), particularly in elderly patients with comorbidities, has not been established. We present the elderly Ph+ MPAL case who discontinued initial treatment with dasatinib and whose disease was successfully controlled by low-dose imatinib with monitoring of drug concentrations in blood.

Peer review status:Published

27 Aug 2020Submitted to Clinical Case Reports
01 Sep 2020Submission Checks Completed
01 Sep 2020Assigned to Editor
16 Nov 2020Reviewer(s) Assigned
02 Dec 2020Review(s) Completed, Editorial Evaluation Pending
30 Dec 2020Editorial Decision: Revise Minor
19 Jan 20211st Revision Received
21 Jan 2021Submission Checks Completed
21 Jan 2021Assigned to Editor
21 Jan 2021Review(s) Completed, Editorial Evaluation Pending
07 Feb 2021Reviewer(s) Assigned
21 Mar 2021Editorial Decision: Accept
May 2021Published in Clinical Case Reports volume 9 issue 5. 10.1002/ccr3.4126